Kexing Biopharm's licensed-in product – Liraglutide Injection receives marketing approval in Peru

Recently, another licensed-in product from Kexing Biopharm Co., Ltd. (688136.SH) - Liraglutide Injection developed by Tonghua Dongbao Pharmaceutical - has been approved for marketing by Peru's National Drug and Medical Device Agency (DIGEMID). This represents a significant breakthrough in Kexing Biopharm's overseas commercialization of diabetes medications.

As a globally recognized GLP-1 receptor agonist, liraglutide's core indication is glycemic control in patients with type 2 diabetes, and it can be used as monotherapy or in combination with other antidiabetic agents to improve blood glucose levels.

Since establishing its overseas collaboration with Tonghua Dongbao, Kexing Biopharm has actively advanced the overseas registration and GMP audits for Liraglutide Injection. In February this year, the product underwent a GMP on-site audit by the Egyptian Ministry of Health; in April, it obtained a GMP certificate from Colombia's National Food and Drug Surveillance Institute (INVIMA); and this month, it passed a GMP on-site audit by Brazil's National Health Surveillance Agency (ANVISA), a PIC/S member country. Coupled with this latest approval in Peru, Liraglutide Injection has achieved successive milestones in its global expansion, embodying the efficient collaboration and joint overseas efforts between Kexing Biopharm and Tonghua Dongbao.